Arbutus to Report Third Quarter 2019 Financial Results
October 30 2019 - 7:30AM
Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus
(HBV) therapeutic solutions company, today announced that it has
scheduled its third quarter financial results, conference call and
webcast for Wednesday, November 6, 2019. The schedule for the
press release and conference call/webcast are as follows:
• |
Q3 2019 Press Release: |
November 6, 2019 at 7:30 a.m. ET |
• |
Q3 2019 Conference Call: |
November 6, 2019 at 8:45 a.m. ET |
• |
Domestic Dial-In Number: |
(866) 393-1607 |
• |
International Dial-In Number: |
(914) 495-8556 |
• |
Conference ID Number: |
7279188 |
A live webcast of the conference call can be
accessed through the Investors section of Arbutus' website at
www.arbutusbio.com.
An archived webcast will be available on the
Arbutus website after the event. Alternatively, you may access a
replay of the conference call by calling (855) 859-2056 or (404)
537-3406, and reference conference ID 7279188.
About ArbutusArbutus Biopharma
Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical
company dedicated to discovering, developing, and commercializing a
cure for patients suffering from chronic Hepatitis B (HBV)
infection. Arbutus is developing multiple drug candidates, each of
which have the potential to improve upon the standard of care and
contribute to a curative combination regimen. For more information,
visit www.arbutusbio.com.
Contact Information
Investors and MediaWilliam H. Collier President
and CEO Phone: 604-419-3200 Email: ir@arbutusbio.com
Pam Murphy Investor Relations Consultant Phone: 604-419-3200
Email: ir@arbutusbio.com
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arbutus Biopharma (NASDAQ:ABUS)
Historical Stock Chart
From Sep 2023 to Sep 2024